Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study

Clinical trial NCT05576389 · RECRUITING

Trial details

NCT number

NCT05576389

Sponsor

Peking University People's Hospital

Status

RECRUITING

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2022-10-01

Primary completion

2027-04-30

Enrollment

64

View on ClinicalTrials.gov